Lixte Biotechnology (NASDAQ:LIXT) Issues Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) released its quarterly earnings data on Tuesday. The company reported ($0.34) EPS for the quarter, FiscalAI reports.

Lixte Biotechnology Price Performance

Shares of LIXT opened at $3.07 on Thursday. The company has a market cap of $22.95 million, a P/E ratio of -2.48 and a beta of 0.86. The stock has a fifty day moving average price of $3.05 and a 200 day moving average price of $3.88. Lixte Biotechnology has a 12 month low of $0.64 and a 12 month high of $6.26.

Hedge Funds Weigh In On Lixte Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of LIXT. Axxcess Wealth Management LLC acquired a new stake in shares of Lixte Biotechnology in the 4th quarter worth about $54,000. XTX Topco Ltd bought a new position in Lixte Biotechnology in the 4th quarter worth about $57,000. Geode Capital Management LLC grew its position in Lixte Biotechnology by 25.9% in the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after purchasing an additional 10,722 shares during the last quarter. DRW Securities LLC increased its stake in shares of Lixte Biotechnology by 11.6% in the fourth quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after purchasing an additional 5,645 shares during the period. Finally, Federation des caisses Desjardins du Quebec raised its holdings in shares of Lixte Biotechnology by 83.6% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock valued at $367,000 after buying an additional 42,530 shares during the last quarter. Institutional investors and hedge funds own 5.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Lixte Biotechnology in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Lixte Biotechnology presently has an average rating of “Sell”.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.